Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex

Journal of Internal Medicine

Volumn 272, Issue 4, 2012, Pages 344-357

  Pagano, S ^a   Satta, N ^a   Werling, D ^b   Offord, V ^b   de Moerloose, P ^a   Charbonney, E ^c   Hochstrasser, D ^a   Roux Lombard, P ^a   Vuilleumier, N ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Anti apolipoprotein A 1 auto antibodies; Atherosclerosis; Inflammation; Molecular mimicry; Myocardial infarction; Toll like receptors

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; APOLIPOPROTEIN A1; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD14 ANTIGEN; CLOPIDOGREL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INSULIN; INTERLEUKIN 6; STROMELYSIN; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIOINFORMATICS; CELL STRAIN HEK293; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR DOCKING; PRIORITY JOURNAL; SIMULATION; STRUCTURAL HOMOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; APOLIPOPROTEIN A-I; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TOLL-LIKE RECEPTOR 2;

EID: 84866340093     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02530.x     Document Type: Article

References (41)

1. Eyre H, Kahn R, Robertson RM et al. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 2004; 109: 3244-55.
2. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218-26.
3. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll like receptor 2. J Clin Invest 2005; 115: 3149-56.
4. Mizoguchi E, Orihara K, Hamasaki S et al. Association between Toll-like receptors and the extent and severity of coronary artery disease in patients with stable angina. Coron Artery Dis 2007; 18: 31-8.
5. Roux-Lombard P, Pagano S, Montecucco F, Satta N, Vuilleumier N. Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases. Clin Rev Allergo Immunol 2010; doi: 10.1007/s12016-010-8233-z, [epub ahead of print].
6. Satta N, Dunoyer-Geindre S, Reber G et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007; 109: 1507-14.
7. Satta N, Kruithof EK, Fickentscher C et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood 2011; 117: 5523-31.
8. O'Neill SG, Giles I, Lambrianides A et al. Antibodies to apolipoprotein A-1, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010; 62: 845-54.
9. Vuilleumier N, Reber G, James R et al. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun 2004; 23: 353-60.
10. Vuilleumier N, Charbonney E, Fontao L et al. Anti-apolipoprotein A-1 IgG are associated with high oxidised low-density lipoprotein levels in acute coronary syndrome. Clin Sci 2008; 115: 25-33.
11. Vuilleumier N, Bratt J, Alizadeh R, Hafstrom I, Jogestrand T, Frostegard J. Anti-ApoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scand J Rheumatol 2010; 39: 447-52.
12. Vuilleumier N, Rossier MF, Pagano S et al. Anti-apolipoprotein A-1 autoantibody of IgG subtype as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 2010; 31: 815-23.
13. Vuilleumier N, Bas S, Pagano S et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients suffering from rheumatoid arthritis. Arthritis Rheum 2010; 62: 2640-50.
14. Montecucco F, Vuilleumier N, Pagano S et al. Anti-ApoA-1 IgG are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 412-21.
15. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007; 17: 253-8.
16. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK. Chemokines in cardiovascular risk prediction. Thromb Haemost 2007; 97: 748-54.
17. Hansson GK. Inflammation, atherosclerosis, and coronary heart disease. N Engl J Med 2005; 352: 1685-95.
18. Soderberg O, Gullberg M, Jarvius M et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006; 3: 995-1000.
19. Fredriksson S, Gullberg M, Jarvius J et al. Protein detection using a proximity-dependent DNA ligation assay. Nat Biotechnol 2002; 20: 473-7.
20. Huang QQ, Sobkoviak R, Jockheck-Clark AR et al. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. J Immunol 2009; 18: 65-73.
21. Berman HM, Westbrook J, Feng Z et al. The protein data bank. Nucleic Acids Res 2000; 28: 235-42.
22. Kirschning CJ, Meng G, Wagner H. TLR2 antagonistic antibody and use thereof. 2005; patent WO 2005/028509.
23. Sircar A, Kim ET, Gray JJ. RosettaAntibody: antibody variable region homology modeling server. Nucleic Acids Res 2009; 37: W474-9.
24. Marcatili P, Rosi A, Tramontano A. PIGS: automatic prediction of antibody structures. Bioinformatics 2008; 24: 1953-4.
25. Whitelegg NR, Rees AR. WAM, an improved algorithm for antibodies modelling on the Web. Protein Eng 2000; 13: 819-24.
26. Tovchigrechko A, Vakser IA. GRAMM-X public web server for protein-protein docking. Nucleic Acids Res 2006; 34: W310-4.
27. Comeau SR, Gatchell DW, Vajda S, Camacho CJ. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res 2004; 32: W96-9.
28. Furenes EB, Arnesen H, Solheim S, Grogaard HK, Hoffmann P, Seljeflot I. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thromb Res 2009; 124: 560-4.
29. Jefferis BJ, Whincup P, Welsh P et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 2010; 208: 557-63.
30. Loftus IM, Naylor AR, Goodall S et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke 2000; 31: 40-7.
31. Samnegard A, Silveira A, Tornvall P, Hamsten A, Ericsson CG, Erikson P. Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 2006; 259: 530-6.
32. Manukyan M, Triantafilou K, Triantafilou M et al. Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1. Eur J Immunol 2005; 35: 911-21.
33. Nakata T, Yasuda M, Fujita M et al. CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptors 2 and 1 without binding to the complex. Cell Microbiol 2006; 8: 1899-909.
34. Maier W, Altwegg LA, Corti R et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005; 111: 1355-61.
35. Yokota S, Minota S, Fujii N. Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors. Int Immunol 2006; 18: 573-80.
36. Raschi E, Testoni C, Bosisio D et al. Role of the MyD88 transduction signalling pathway in endothelial activation by anti-phospholipid antibodies. Blood 2003; 101: 3495-500.
37. Jiang Q, Akashi S, Miyake K, Petty HR. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol 2000; 165: 3541-4.
38. Piccinini AM, Midwoods KS. DAMPenig inflammation by modulating TLR signalling. Mediators Inflamm 2010; doi: 10.1155/2010/672395. [Epub ahead of print].
39. Biasucci LM, Liuzzo G, Fantuzzi G et al. Increasing levels of interleukin (IL)-1 Ra and IL-6 during the first 2days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079-84.
40. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunization. Atherosclerosis 2002; 167: 177-85.
41. Meroni PL, Raschi E, Testoni C, Parisio A, Borghi MO. Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmun Rev 2004; 3: 510-5.